Wu Ling, Chen Hongyao, Zhang Jingting, Tang Jincheng, Wang Zhibin, Xue Peisen, Gao Wenhui, Yang Renyi, Zeng Puhua
Hunan Provincial Hospital of Integrated Traditional Chinese and Western Medicine, Hunan Academy of Chinese Medicine, Changsha, Hunan, China.
Hunan Provincial Key Laboratory of Traditional Chinese Medicine Formula and Syndrome Research in Translational Medicine, Hunan University of Chinese Medicine, Changsha, Hunan, China.
Front Pharmacol. 2025 Jun 26;16:1636149. doi: 10.3389/fphar.2025.1636149. eCollection 2025.
BACKGROUND: Hepatocellular carcinoma (HCC) is a prevalent malignant tumor globally, with high incidence and mortality rates that seriously endanger human health. While traditional therapeutic approaches have demonstrated some efficacy in controlling disease progression, they are still fraught with numerous limitations. In recent years, plant-derived nanovesicles have garnered significant attention owing to their distinctive biological activities and promising antitumor characteristics. The effects of , a plant with various medicinal values, and its-derived nanovesicles (FdNVs) on HCC cells have not been clarified. OBJECTIVE: This study aimed to explore the inhibitory effects of FdNVs on human HCC cells and subcutaneous xenograft tumors, as well as the underlying molecular mechanisms. METHODS: FdNVs were isolated and purified through ultracentrifugation, characterized via Nanoparticle Tracking Analysis (NTA) and Transmission Electron Microscopy (TEM), and subsequently evaluated using the HepG2 HCC cell line to assess their effects on proliferation (via cell viability, EdU, and colony formation assays), migration (wound healing assay), and invasion (Transwell assay), while mitochondrial ultrastructural changes were examined by TEM, intracellular ROS and Fe levels were measured fluorometrically, oxidative stress markers (GSH and MDA) were quantified colorimetrically, ferroptosis-related mRNA and protein expression were analyzed by RT-qPCR and Western blot, followed by validation of their antitumor efficacy in a nude mouse HepG2 xenograft model. RESULTS: studies demonstrated that FdNVs dose-dependently suppressed HepG2 cell proliferation, motility, and invasive capacity. Mechanistic investigations revealed that this inhibitory effect was mediated through ferroptosis activation, supported by the following observations: elevated intracellular ferrous iron (Fe) and reactive oxygen species (ROS), reduced glutathione (GSH) content, disrupted mitochondrial ultrastructure, and modulated expression of key ferroptosis regulators-including upregulation of pro-ferroptotic proteins (p53 and ALOX15) and downregulation of anti-ferroptotic factors (xCT and GPX4). Furthermore, studies validated the tumor-suppressive role of FdNVs, confirming their capacity to trigger ferroptosis in HepG2 xenografts. CONCLUSION: FdNVs inhibited the proliferation, migration and invasion of HCC cells by inducing iron death, and their anti-tumor mechanism involved the regulation of iron death-related genes and proteins.
背景:肝细胞癌(HCC)是全球一种常见的恶性肿瘤,发病率和死亡率高,严重危害人类健康。虽然传统治疗方法在控制疾病进展方面已显示出一定疗效,但仍存在许多局限性。近年来,植物源纳米囊泡因其独特的生物学活性和有前景的抗肿瘤特性而备受关注。具有多种药用价值的植物及其衍生的纳米囊泡(FdNVs)对肝癌细胞的影响尚未阐明。 目的:本研究旨在探讨FdNVs对人肝癌细胞和皮下异种移植瘤的抑制作用及其潜在的分子机制。 方法:通过超速离心分离和纯化FdNVs,通过纳米颗粒跟踪分析(NTA)和透射电子显微镜(TEM)进行表征,随后使用HepG2肝癌细胞系评估其对增殖(通过细胞活力、EdU和集落形成试验)、迁移(伤口愈合试验)和侵袭(Transwell试验)的影响,同时通过TEM检查线粒体超微结构变化,通过荧光法测量细胞内ROS和铁水平,通过比色法定量氧化应激标志物(GSH和MDA),通过RT-qPCR和蛋白质印迹分析铁死亡相关mRNA和蛋白质表达,随后在裸鼠HepG2异种移植模型中验证其抗肿瘤疗效。 结果:研究表明,FdNVs剂量依赖性地抑制HepG2细胞增殖、运动性和侵袭能力。机制研究表明,这种抑制作用是通过铁死亡激活介导的,以下观察结果支持这一点:细胞内亚铁离子(Fe)和活性氧(ROS)升高,谷胱甘肽(GSH)含量降低,线粒体超微结构破坏,以及关键铁死亡调节因子的表达受到调节,包括促铁死亡蛋白(p53和ALOX15)上调和抗铁死亡因子(xCT和GPX4)下调。此外,研究验证了FdNVs的肿瘤抑制作用,证实了它们在HepG2异种移植瘤中触发铁死亡的能力。 结论:FdNVs通过诱导铁死亡抑制肝癌细胞的增殖、迁移和侵袭,其抗肿瘤机制涉及铁死亡相关基因和蛋白质的调节。
J Ethnopharmacol. 2025-6-19
Front Biosci (Landmark Ed). 2025-6-27
Front Cell Dev Biol. 2025-6-3
Front Biosci (Landmark Ed). 2025-6-17
Cancer Gene Ther. 2025-4
Clin Transl Med. 2025-3
BMC Biol. 2025-2-24
Front Bioeng Biotechnol. 2025-1-20
Nat Commun. 2025-1-20
Clin Mol Hepatol. 2025-2